{"id":"urate-oxidase","safety":{"commonSideEffects":[{"rate":null,"effect":"Allergic reactions (including anaphylaxis)"},{"rate":null,"effect":"Hemolysis"},{"rate":null,"effect":"Methemoglobinemia"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Urate oxidase is a recombinant enzyme that breaks down uric acid by oxidizing it to allantoin, which is approximately 5–10 times more soluble than uric acid. This mechanism rapidly lowers serum and urine uric acid levels, preventing uric acid crystal formation and the complications of tumor lysis syndrome or severe hyperuricemia.","oneSentence":"Urate oxidase catalyzes the conversion of uric acid to allantoin, a more soluble compound that is readily excreted in urine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:38.692Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tumor lysis syndrome prophylaxis and treatment in patients with hematologic malignancies at high risk of hyperuricemia"},{"name":"Severe hyperuricemia in gout or other conditions"}]},"trialDetails":[{"nctId":"NCT07116746","phase":"PHASE2","title":"Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients","status":"RECRUITING","sponsor":"Arthrosi Therapeutics","startDate":"2025-12-03","conditions":"Gout, Gouty Arthritis, Hyperuricemia","enrollment":25},{"nctId":"NCT07280156","phase":"PHASE2","title":"A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)","status":"RECRUITING","sponsor":"Protalix","startDate":"2025-12-22","conditions":"Gout","enrollment":150},{"nctId":"NCT07369622","phase":"PHASE4","title":"HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness","status":"NOT_YET_RECRUITING","sponsor":"Haiphong University of Medicine and Pharmacy","startDate":"2026-01-20","conditions":"Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis, Gout and Hyperuricemia","enrollment":228},{"nctId":"NCT05999851","phase":"NA","title":"Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2023-09-01","conditions":"Preeclampsia, Hypertensive Disorder of Pregnancy","enrollment":400},{"nctId":"NCT04745910","phase":"PHASE4","title":"Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-04-05","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Tumor Lysis Syndrome","enrollment":10},{"nctId":"NCT01046825","phase":"PHASE2, PHASE3","title":"Mature B-Cell Lymphoma And Leukemia Study III","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2010-09-09","conditions":"Mature B-Cell Lymphoma","enrollment":128},{"nctId":"NCT04596540","phase":"PHASE3","title":"A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2020-11-30","conditions":"Chronic Gout","enrollment":153},{"nctId":"NCT04513366","phase":"PHASE3","title":"A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2020-08-18","conditions":"Chronic Gout","enrollment":112},{"nctId":"NCT06995339","phase":"PHASE2","title":"Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2025-05-30","conditions":"Gout","enrollment":60},{"nctId":"NCT06629376","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia","status":"RECRUITING","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2023-11-20","conditions":"Gout, Hyperuricemia","enrollment":60},{"nctId":"NCT05745727","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels","status":"COMPLETED","sponsor":"Protalix","startDate":"2023-03-23","conditions":"Gout","enrollment":64},{"nctId":"NCT05690204","phase":"PHASE2","title":"Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanton Pharma Pte. Ltd.","startDate":"2022-12-12","conditions":"Gout","enrollment":87},{"nctId":"NCT03418779","phase":"PHASE2, PHASE3","title":"Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2019-07-04","conditions":"IgA Nephropathy at High Risk of Developing ESRD","enrollment":60},{"nctId":"NCT04987294","phase":"PHASE2","title":"Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease","status":"TERMINATED","sponsor":"Allena Pharmaceuticals","startDate":"2022-09-02","conditions":"Hyperuricemia, Gout, Chronic Kidney Diseases","enrollment":19},{"nctId":"NCT04987242","phase":"PHASE2","title":"An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201)","status":"COMPLETED","sponsor":"Allena Pharmaceuticals","startDate":"2021-07-16","conditions":"Hyperuricemia, Gout, Chronic Kidney Diseases","enrollment":16},{"nctId":"NCT05312268","phase":"PHASE4","title":"Rasburicase Treatment in Chronic Gouty Arthritis","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-06-15","conditions":"Chronic Gout","enrollment":60},{"nctId":"NCT00199043","phase":"PHASE3","title":"Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma","status":"COMPLETED","sponsor":"Goethe University","startDate":"2003-05","conditions":"Adult Acute Lymphocytic Leukemia, High-grade Lymphoma","enrollment":80},{"nctId":"NCT05168683","phase":"PHASE1","title":"Scintigraphy Study in Healthy Volunteers to Characterize the Performance of ALLN-346 Tablets","status":"COMPLETED","sponsor":"Allena Pharmaceuticals","startDate":"2022-01-11","conditions":"Hyperuricemia, Gout","enrollment":12},{"nctId":"NCT04463940","phase":"","title":"Xanthine Oxidase and Uric Acid Origin in Preeclamptic Women","status":"UNKNOWN","sponsor":"Barzilai Medical Center","startDate":"2020-06-30","conditions":"Pre-Eclampsia, Hyperuricemia","enrollment":100},{"nctId":"NCT04349306","phase":"PHASE4","title":"Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-05-14","conditions":"Lymphoma","enrollment":50},{"nctId":"NCT05226013","phase":"PHASE1","title":"Tolerance, Pharmacokinetics / Pharmacodynamics (PK / PD) and Immunogenicity of Pegylated Uric Acid Oxidase for Injection in Healthy Adults and Hyperuricemia Volunteers","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2021-12-08","conditions":"Hyperuricemia","enrollment":54},{"nctId":"NCT03226899","phase":"PHASE4","title":"A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment","status":"TERMINATED","sponsor":"Ironwood Pharmaceuticals, Inc.","startDate":"2017-07-19","conditions":"Gout, Chronic Kidney Disease (CKD)","enrollment":242},{"nctId":"NCT04236219","phase":"PHASE1","title":"ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Allena Pharmaceuticals","startDate":"2020-09-02","conditions":"Hyperuricemia","enrollment":24},{"nctId":"NCT04047394","phase":"PHASE1","title":"A Study to Determine the Safety, Tolerability, PK and Preliminary PD of SSS11 in Chinese Healthy Adult Volunteers","status":"UNKNOWN","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2019-10-22","conditions":"Gout","enrollment":33},{"nctId":"NCT04829435","phase":"PHASE1","title":"Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)","status":"COMPLETED","sponsor":"Allena Pharmaceuticals","startDate":"2021-04-21","conditions":"Hyperuricemia, Gout","enrollment":18},{"nctId":"NCT02297126","phase":"NA","title":"A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-03","conditions":"Adverse Drug Reaction","enrollment":4465},{"nctId":"NCT03395977","phase":"NA","title":"Uric Acid Effects on Endothelium and Oxydative Stress","status":"COMPLETED","sponsor":"Erasme University Hospital","startDate":"2018-01-03","conditions":"Oxidative Stress, Endothelial Function, Cardiovascular System","enrollment":53},{"nctId":"NCT01200485","phase":"PHASE2","title":"Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-04","conditions":"Leukemia, Lymphoma","enrollment":55},{"nctId":"NCT01472692","phase":"PHASE4","title":"Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2011-10","conditions":"Prehypertension, Gout, Pulse Wave Velocity","enrollment":47},{"nctId":"NCT03316131","phase":"PHASE2","title":"A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-10-25","conditions":"Asymptomatic Hyperuricemia","enrollment":36},{"nctId":"NCT02338323","phase":"NA","title":"Compare the Renal Protective Effects of Febuxostat and Benzbromarone","status":"COMPLETED","sponsor":"Shanghai 10th People's Hospital","startDate":"2015-01","conditions":"Chronic Kidney Disease, Hyperuricemia, Abnormal Renal Function","enrollment":160},{"nctId":"NCT01931527","phase":"NA","title":"Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2006-07","conditions":"Obesity, Metabolic Syndrome, Hyperuricemia","enrollment":31},{"nctId":"NCT01323335","phase":"PHASE1","title":"The Relationship Between Uric Acid and Inflammatory Markers","status":"COMPLETED","sponsor":"National Institute on Aging (NIA)","startDate":"2009-03-31","conditions":"Healthy Volunteers","enrollment":97},{"nctId":"NCT02373384","phase":"PHASE4","title":"The Predictors of Successful Oral Dissolution Therapy in Radiolucent Renal Stones; A Prospective Evaluation","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2015-02","conditions":"Urolithiasis, Renal Stones","enrollment":182},{"nctId":"NCT01564277","phase":"PHASE2","title":"Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2011-09-29","conditions":"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","enrollment":24},{"nctId":"NCT03361618","phase":"NA","title":"Effect of Oral Zinc Sulfate Supplementation on Enzymes of Urate Pathway","status":"COMPLETED","sponsor":"Babylon University","startDate":"2011-07-01","conditions":"Infertility Unexplained","enrollment":120},{"nctId":"NCT01228903","phase":"NA","title":"Uric Acid and the Endothelium in CKD","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2010-10","conditions":"Kidney Disease","enrollment":80},{"nctId":"NCT00513474","phase":"PHASE1","title":"Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2008-01","conditions":"Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia","enrollment":46},{"nctId":"NCT00186940","phase":"","title":"Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2005-03","conditions":"Leukemia, Lymphoma, Tumor Lysis Syndrome","enrollment":16},{"nctId":"NCT02944214","phase":"NA","title":"Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients","status":"UNKNOWN","sponsor":"Shanghai 10th People's Hospital","startDate":"2016-10","conditions":"Chronic Kidney Disease, Hyperuricemia, Abnormal Renal Function","enrollment":800},{"nctId":"NCT02464605","phase":"PHASE1","title":"Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels","status":"COMPLETED","sponsor":"Selecta Biosciences, Inc.","startDate":"2015-05","conditions":"Gout","enrollment":22},{"nctId":"NCT01830725","phase":"","title":"Purine Metabolism Enzyme SNP to Uric Acid Production","status":"COMPLETED","sponsor":"Keesler Air Force Base Medical Center","startDate":"2012-12","conditions":"Gout, Hyperuricemia","enrollment":100},{"nctId":"NCT02082769","phase":"PHASE3","title":"Safety and Efficacy of Oral Febuxostat in Subjects With Gout","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2011-07","conditions":"Gout","enrollment":504},{"nctId":"NCT00921375","phase":"PHASE3","title":"Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia","status":"COMPLETED","sponsor":"Virchow Group","startDate":"2010-02","conditions":"Hyperuricemia","enrollment":100},{"nctId":"NCT02147002","phase":"NA","title":"Omega-3 Acids and Cardio - Vascular Complications in Patients With Chronic Kidney Disease in Stage 1-3","status":"UNKNOWN","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2012-10","conditions":"Chronic Kidney Disease, Cardiovascular Complications","enrollment":120},{"nctId":"NCT00987415","phase":"PHASE2","title":"Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels","status":"COMPLETED","sponsor":"Duke University","startDate":"2010-05","conditions":"Heart Failure, Elevated Serum Uric Acid","enrollment":253},{"nctId":"NCT01736514","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout","status":"COMPLETED","sponsor":"Astellas Pharma Taiwan, Inc.","startDate":"2011-03","conditions":"Gout","enrollment":109},{"nctId":"NCT00111657","phase":"PHASE2","title":"Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout","status":"COMPLETED","sponsor":"John Sundy","startDate":"2004-12","conditions":"Gout","enrollment":30},{"nctId":"NCT00057811","phase":"PHASE2","title":"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2004-06","conditions":"Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma","enrollment":97},{"nctId":"NCT02060552","phase":"PHASE4","title":"Immune Molecular and Inflammatory Cytokines Dysfunction Analysis in Gout Patients With Different Urate Levels","status":"COMPLETED","sponsor":"Tongji Hospital","startDate":"2013-01","conditions":"Primary Gout","enrollment":96},{"nctId":"NCT00607152","phase":"PHASE3","title":"Rasburicase (Fasturtec) Registration Trial","status":"TERMINATED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Hyperuricemia","enrollment":10},{"nctId":"NCT00628628","phase":"PHASE2","title":"Rasburicase in Patients at Risk for Tumor Lysis Syndrome","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-01","conditions":"Tumor Lysis Syndrome","enrollment":82},{"nctId":"NCT01363869","phase":"NA","title":"Effects of Green Tea on Level of Serum Uric Acid in Healthy Individuals","status":"COMPLETED","sponsor":"Chiang Mai University","startDate":"2011-06","conditions":"Hyperuricemia, Gout","enrollment":30},{"nctId":"NCT01097369","phase":"","title":"Elitek (Rasburicase) Immuno-Monitoring Study","status":"TERMINATED","sponsor":"Sanofi","startDate":"2010-02","conditions":"Tumor Lysis Syndrome","enrollment":1},{"nctId":"NCT00756964","phase":"PHASE2","title":"Lowering Serum Uric Acid to Prevent Acute Kidney Injury","status":"COMPLETED","sponsor":"University of Florida","startDate":"2008-10","conditions":"Hyperuricemia","enrollment":26},{"nctId":"NCT00360438","phase":"PHASE1, PHASE2","title":"Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-07","conditions":"Leukemia, Lymphoma, Tumor Lysis Syndrome","enrollment":18},{"nctId":"NCT00664144","phase":"PHASE2","title":"Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Sanofi","startDate":"2002-07","conditions":"Hyperuricemia","enrollment":33},{"nctId":"NCT00174915","phase":"PHASE3","title":"Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.","status":"COMPLETED","sponsor":"Takeda","startDate":"2003-02","conditions":"Gout","enrollment":1072},{"nctId":"NCT00102440","phase":"PHASE3","title":"Febuxostat Versus Allopurinol Control Trial in Subjects With Gout","status":"COMPLETED","sponsor":"Takeda","startDate":"2002-07","conditions":"Gout","enrollment":760},{"nctId":"NCT01523327","phase":"","title":"Study of Association Between Maternal Uric Acid , Maternal and Fetal Outcome in Pregnant Women With Hypertension","status":"UNKNOWN","sponsor":"Ain Shams Maternity Hospital","startDate":"2011-10","conditions":"Uric Acid and Hypertension in Pregnancy","enrollment":80},{"nctId":"NCT01356498","phase":"PHASE3","title":"Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout","status":"COMPLETED","sponsor":"Savient Pharmaceuticals","startDate":"2006-12","conditions":"Gout","enrollment":151},{"nctId":"NCT00174967","phase":"PHASE2","title":"Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout","status":"COMPLETED","sponsor":"Takeda","startDate":"2001-01","conditions":"Gout","enrollment":153},{"nctId":"NCT00325195","phase":"PHASE3","title":"Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout","status":"COMPLETED","sponsor":"Savient Pharmaceuticals","startDate":"2006-05","conditions":"Gout","enrollment":225},{"nctId":"NCT00174941","phase":"PHASE2","title":"Long-Term Safety of Febuxostat in Subjects With Gout.","status":"COMPLETED","sponsor":"Takeda","startDate":"2001-03","conditions":"Gout","enrollment":116},{"nctId":"NCT00175019","phase":"PHASE3","title":"Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010","status":"COMPLETED","sponsor":"Takeda","startDate":"2003-07","conditions":"Gout","enrollment":1086},{"nctId":"NCT01021241","phase":"PHASE1","title":"Safety and Efficacy Study of Intravenous Uricase-PEG 20","status":"UNKNOWN","sponsor":"EnzymeRx","startDate":"2009-10","conditions":"Gout, Hyperuricemia","enrollment":20},{"nctId":"NCT00230178","phase":"PHASE3","title":"Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-04","conditions":"Tumor Lysis Syndrome, Cancer, Hyperuricemia","enrollment":280},{"nctId":"NCT01038947","phase":"PHASE1","title":"Safety and Efficacy Study of Intramuscular Uricase-PEG 20","status":"UNKNOWN","sponsor":"EnzymeRx","startDate":"2009-12","conditions":"Gout, Hyperuricemia","enrollment":28},{"nctId":"NCT00631579","phase":"PHASE2","title":"Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-04","conditions":"Hyperuricemia, Leukemia, Lymphoma","enrollment":50},{"nctId":"NCT00302653","phase":"PHASE4","title":"Rasburicase in Tumor Lysis Syndrome","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-02","conditions":"Hyperuricemia","enrollment":33},{"nctId":"NCT00978653","phase":"NA","title":"The Effect of Uric Acid Decrement on Endothelial Function in Patients With Chronic Renal Failure","status":"COMPLETED","sponsor":"Istanbul University","startDate":"2008-04","conditions":"Hyperuricemia, Chronic Kidney Disease","enrollment":20},{"nctId":"NCT00290992","phase":"PHASE2","title":"Rasburicase for Hyperuricemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-06","conditions":"Nutritional and Metabolic Diseases","enrollment":30},{"nctId":"NCT00230217","phase":"PHASE4","title":"Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-03","conditions":"Tumors, Hyperuricemia, Tumor Lysis Syndrome","enrollment":94},{"nctId":"NCT00651911","phase":"PHASE4","title":"Fasturtec TLS Treatment / Prophylysis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-07","conditions":"Tumor Lysis Syndrome","enrollment":45},{"nctId":"NCT00563771","phase":"PHASE4","title":"Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-03","conditions":"Hyperuricemia","enrollment":38}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"BLINDNESS"},{"count":3,"reaction":"GASTROINTESTINAL DISORDER"},{"count":3,"reaction":"MULTI-ORGAN FAILURE"},{"count":3,"reaction":"PYREXIA"},{"count":2,"reaction":"CEREBRAL HAEMORRHAGE"},{"count":2,"reaction":"ELECTROENCEPHALOGRAM ABNORMAL"},{"count":2,"reaction":"NECROSIS"},{"count":2,"reaction":"OPTIC NERVE INJURY"},{"count":2,"reaction":"PETIT MAL EPILEPSY"},{"count":1,"reaction":"BLOOD ALKALINE PHOSPHATASE INCREASED"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["rasburicase"],"phase":"marketed","status":"active","brandName":"urate oxidase","genericName":"urate oxidase","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Urate oxidase catalyzes the conversion of uric acid to allantoin, a more soluble compound that is readily excreted in urine. Used for Tumor lysis syndrome prophylaxis and treatment in patients with hematologic malignancies at high risk of hyperuricemia, Severe hyperuricemia in gout or other conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}